Researchers have unearthed how the SARS-CoV-2 virus employs genomic "origami" to infect and replicate inside host cells, a discovery that may hold the key to developing novel antiviral drugs that target specific areas of the virus's genomic structure. The findings were published on November 5 in Molecular Cell.  

Gene therapies offer great benefits to patients but could strain healthcare budgets and exacerbate existing treatment inequities in Canada, according to an expert panel that was commissioned to write a report by the Council of Canadian Academies.  

Why does the SARS-CoV-2 virus seem to have less of an impact on children than adults? A new study published November 5 in Nature Immunology investigates this question, finding that the immune systems of children respond differently to SARS-CoV-2 in a way that allows them to more easily clear the virus from their bodies.  

Novartis has released new data from an interim analysis of its randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of canakinumab (Ilaris), a monoclonal antibody (mAb) in hospitalized patients with COVID-19.  

Large-scale profiling of protein changes in response to drug treatment in cancer cell lines has been demonstrated as a powerful tool to predict drug sensitivity, understand drug resistance, and identify optimal drug combinations. The analysis was published in Cancer Cell on November 5.  

ABL Europe in France is collaborating with the University Clinic of Tuebingen and Prime Vector Technologies of Germany on a viral vector SARS-CoV-2 vaccine.  

Avectas has become a resident at Johnson & Johnson Innovation (JLABS), a 40,000-sq-ft life science innovation center in Toronto, Canada.  

Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.  

ProteoNic has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences.  

Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing facility in Mississauga, Canada.  

Researchers have unearthed how the SARS-CoV-2 virus employs genomic "origami" to infect and replicate inside host cells, a discovery that may hold the key to developing novel antiviral drugs that target specific areas of the virus's genomic structure. The findings were published on November 5 in Molecular Cell.  

Gene therapies offer great benefits to patients but could strain healthcare budgets and exacerbate existing treatment inequities in Canada, according to an expert panel that was commissioned to write a report by the Council of Canadian Academies.  

Senhwa Biosciences along with its clinical partner Center for Advanced Research and Education in Gainesville, GA, received a "study may proceed" letter from the U.S. Food and Drug Administration for its phase II investigator-initiated trial. The trial will evaluate the effectiveness of silmitasertib, an orally available casein kinase 2 inhibitor, to treat moderate COVID-19 patients.  

Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody (mAb) ahead of a potential emergency use authorization to treat COVID-19.